Considering TWEAK as a target for therapy in renal and vascular injury

Cytokine Growth Factor Rev. 2009 Jun;20(3):251-8. doi: 10.1016/j.cytogfr.2009.05.002. Epub 2009 May 30.

Abstract

TWEAK is a cytokine of the TNF superfamily that activates the Fn14 receptor. TWEAK may regulate cell proliferation, cell death, cell differentiation, angiogenesis and inflammation. The expression of TWEAK and Fn14 is increased during vascular and renal injury. Inflammatory cytokines increase Fn14 receptor expression in tubular and vascular smooth muscle cells. Moreover, TWEAK induces tubular cell apoptosis under proinflammatory conditions. TWEAK itself contributes to renal and vascular inflammation by promoting chemokine and inflammatory cytokine secretion. Confirmation of its role in acute kidney injury and atherosclerotic lesions formation came from functional studies in experimental animal models. The available evidence suggests that TWEAK might be a target for therapeutic intervention in renal and vascular injury and its role in different forms of tissue damage should be further explored.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Apoptosis
  • Cell Proliferation
  • Cytokine TWEAK
  • Humans
  • Kidney Diseases / drug therapy
  • Kidney Diseases / metabolism*
  • Kidney Diseases / pathology
  • Models, Biological
  • Receptors, Tumor Necrosis Factor / metabolism
  • TWEAK Receptor
  • Tumor Necrosis Factor Inhibitors
  • Tumor Necrosis Factors / metabolism*
  • Vascular Diseases / drug therapy
  • Vascular Diseases / metabolism*
  • Vascular Diseases / pathology

Substances

  • Cytokine TWEAK
  • Receptors, Tumor Necrosis Factor
  • TNFRSF12A protein, human
  • TNFSF12 protein, human
  • TWEAK Receptor
  • Tumor Necrosis Factor Inhibitors
  • Tumor Necrosis Factors